44 related articles for article (PubMed ID: 12374700)
1. Editorial for "Potential Antihuman Epidermal Growth Factor Receptor 2 Target Therapy Beneficiaries: The Role of MRI-Based Radiomics in Distinguishing Human Epidermal Growth Factor Receptor 2-Low Status of Breast Cancer".
Geitung JT
J Magn Reson Imaging; 2023 Nov; 58(5):1615-1616. PubMed ID: 36744580
[No Abstract] [Full Text] [Related]
2. Erythrose inhibits the progression to invasiveness and reverts drug resistance of cancer stem cells of glioblastoma.
Gallardo-Pérez JC; Trejo-Solís MC; Robledo-Cadena DX; López-Marure R; Agredano-Moreno LT; Jimenez-García LF; Sánchez-Lozada LG
Med Oncol; 2023 Feb; 40(3):104. PubMed ID: 36821013
[TBL] [Abstract][Full Text] [Related]
3. Glucose metabolic phenotype of pancreatic cancer.
Chan AK; Bruce JI; Siriwardena AK
World J Gastroenterol; 2016 Mar; 22(12):3471-85. PubMed ID: 27022229
[TBL] [Abstract][Full Text] [Related]
4. Heparan sulfate mediates trastuzumab effect in breast cancer cells.
Suarez ER; Paredes-Gamero EJ; Del Giglio A; Tersariol IL; Nader HB; Pinhal MA
BMC Cancer; 2013 Oct; 13():444. PubMed ID: 24083474
[TBL] [Abstract][Full Text] [Related]
5. Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells.
Kho DH; Nangia-Makker P; Balan V; Hogan V; Tait L; Wang Y; Raz A
Cancer Res; 2013 Feb; 73(4):1411-9. PubMed ID: 23248119
[TBL] [Abstract][Full Text] [Related]
6. Human responses against HER-2-positive cancer cells in human immune system-engrafted mice.
De Giovanni C; Nicoletti G; Landuzzi L; Romani F; Croci S; Palladini A; Murgo A; Antognoli A; Ianzano ML; Stivani V; Grosso V; Iezzi M; Stramucci L; Barbieri E; Lemoli RM; Nanni P; Lollini PL
Br J Cancer; 2012 Oct; 107(8):1302-9. PubMed ID: 22929887
[TBL] [Abstract][Full Text] [Related]
7. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells.
Ahmad A; Aboukameel A; Kong D; Wang Z; Sethi S; Chen W; Sarkar FH; Raz A
Cancer Res; 2011 May; 71(9):3400-9. PubMed ID: 21389093
[TBL] [Abstract][Full Text] [Related]
8. Lost in migration.
Mack GS; Marshall A
Nat Biotechnol; 2010 Mar; 28(3):214-29. PubMed ID: 20212481
[No Abstract] [Full Text] [Related]
9. Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy.
Iiizumi M; Liu W; Pai SK; Furuta E; Watabe K
Biochim Biophys Acta; 2008 Dec; 1786(2):87-104. PubMed ID: 18692117
[TBL] [Abstract][Full Text] [Related]
10. Roles for neuregulins in human cancer.
Stove C; Bracke M
Clin Exp Metastasis; 2004; 21(8):665-84. PubMed ID: 16035612
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
12. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
13. New insights into anti-HER-2 receptor monoclonal antibody research.
Kumar R; Mandal M; Vadlamudi R
Semin Oncol; 2000 Dec; 27(6 Suppl 11):84-91; discussion 92-100. PubMed ID: 11236033
[TBL] [Abstract][Full Text] [Related]
14. Antihuman epidermal growth factor receptor 2 antibody herceptin inhibits autocrine motility factor (AMF) expression and potentiates antitumor effects of AMF inhibitors.
Talukder AH; Bagheri-Yarmand R; Williams RR; Ragoussis J; Kumar R; Raz A
Clin Cancer Res; 2002 Oct; 8(10):3285-9. PubMed ID: 12374700
[TBL] [Abstract][Full Text] [Related]
15. Heregulin regulation of autocrine motility factor expression in human tumor cells.
Talukder AH; Adam L; Raz A; Kumar R
Cancer Res; 2000 Jan; 60(2):474-80. PubMed ID: 10667603
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
